Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2024-05-13 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
We refer to our letter dated 26th April 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting ....
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication from Sanofi India Limited dated May 13, 2024, addressed to stock exchanges, announcing the outcome of a Board Meeting held on the same day. The key content includes approval of the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended March 31, 2024, along with a Limited Review Report by the statutory auditors. The document references compliance with SEBI regulations and includes notes on accounting standards and exceptional items. The length of the document (8276 characters) and the inclusion of detailed financial results and auditor review indicate it is a substantive financial report rather than a brief announcement. The document is not a full annual report but an interim quarterly financial report with actual financial data and auditor review, fitting the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-05-13 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issue of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI regulations and provides details of shareholders and share certificate numbers. There is no financial data, no discussion of company performance, no voting results, no management changes, and no mention of any report publication. The content is a regulatory announcement about share certificate issuance, which fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories.
2024-05-09 English
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share ....
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issue of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI regulations and provides details of shareholders and share certificate numbers. There is no financial data, no discussion of company performance, no voting results, no management changes, no earnings information, or any other report content. The document is an official notification about share certificate issuance, which fits the category of Share Issue/Capital Change announcements. The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-05-09 English
Scheme of Arrangement
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges referencing a judicial pronouncement by the National Company Law Tribunal (NCLT) approving a Scheme of Arrangement between Sanofi India Limited and its subsidiary. It mentions prior communications under Regulation 30 of SEBI (LODR) Regulations and informs about the sanction order being uploaded on the NCLT website. The document is only 2166 characters long and does not contain any financial data, detailed report content, or analysis. It is essentially an announcement of a regulatory event related to corporate restructuring (Scheme of Arrangement) and does not itself constitute a merger filing or detailed merger documentation. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) under SEBI LODR disclosures, which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories. It is not a full merger filing (MA or TAR), nor a report publication announcement (RPA) since it does not announce a report publication but a judicial order approval. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-05-09 English
Judicial pronouncement by the Hon''ble National Company Law Tribunal, Mumbai bench, approving the Scheme of Arrangement ("Scheme") between Sanofi India Limited and Sanofi Consumer Healthcare ....
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a judicial pronouncement by the National Company Law Tribunal approving a Scheme of Arrangement (demerger) between Sanofi India Limited and its subsidiary. The document is short (2166 characters) and serves as a disclosure or announcement rather than a detailed report. It does not contain financial statements, detailed analysis, or comprehensive data. It is an update on a regulatory/legal event related to corporate restructuring. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a short notice dated 7th May 2024 informing stock exchanges about an upcoming investor/analysts call on the financial results for the quarter ended 31st March 2024. It provides details about the date, time, and registration for the call but does not contain any financial data or the actual results. The document is an announcement of an event related to financial results, not the results themselves or a detailed report. According to the rules, such announcements about calls or presentations are best classified as Investor Presentation (IP) since it is about a detailed presentation for investors focusing on financials and strategy. The document length is short (2106 characters), and it is not a report publication announcement or a certification. Therefore, the appropriate classification is Investor Presentation (IP).
2024-05-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.